Medical Imaging (MEDD) 10-Q 23 Jul 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Jun. 27, 2018
Document And Entity Information
Entity Registrant Name	MEDICAL IMAGING CORP.
Entity Central Index Key	1,370,804
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		38,996,608
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,018

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current Assets
Cash and Cash Equivalents	$ 61,535	$ 34,956
Accounts Receivable, net of allowance for doubtful accounts	907,946	945,392
Prepaid Expenses	19,104	52,587
Total Current Assets	988,585	1,032,935
Property and Equipment, net of accumulated depreciation	1,608,350	1,710,917
Goodwill	1,422,670	1,422,670
Deposits	24,866	25,105
TOTAL ASSETS	4,044,471	4,191,627
Current Liabilities
Bank Overdraft	35,171	0
Accounts Payable	2,526,251	2,308,276
Accrued Liabilities	1,056,615	950,137
Current Portion of Capital Lease Obligations	136,580	143,501
Current Portion of Promissory Notes	251,721	287,523
Current Portion of Promissory Notes, Overdue	671,150	782,000
Current Portion of Royalty Financing	1,467,724	1,324,768
Current Portion of Convertible Notes	164,069	145,131
Current Portion of Convertible Notes, Overdue	2,101,056	2,086,000
Derivative Liability	116,803	0
Total Current Liabilities	8,527,140	8,027,336
Long Term Liabilities
Capital Lease Obligations, less current portion	73,767	103,735
Promissory Notes, less current portion, net of unamortized discounts	100,000	100,000
Royalty Financing, less current portion, net of unamortized discounts	1,071,393	1,108,015
Convertible Notes, less current portion, net of unamortized discounts	25,000	178,000
Total Liabilities	9,797,300	9,517,086
Commitments and Contingencies
Stockholders' Deficit
Preferred Stock	0	0
Common Stock	38,997	33,297
Additional Paid-In Capital	2,762,348	2,591,206
Accumulated Other Comprehensive Income	237,028	184,054
Accumulated Deficit	(8,791,202)	(8,134,016)
Total Stockholders' Deficit	(5,752,829)	(5,325,459)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 4,044,471	$ 4,191,627

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value in dollars	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value in dollars	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	38,996,608	33,296,481
Common stock, shares outstanding	38,996,608	33,296,481
Doubtful accounts, accounts receivable	$ 628,480	$ 596,866
Accumulated depreciation, property and equipment	2,098,945	1,985,408
Promissory Notes
Unamortized discount, current	90,418	85,360
Unamortized discount, noncurrent	65,000	65,000
Royalty Financing
Unamortized discount, current	425,337	425,337
Unamortized discount, noncurrent	4,345,841	4,452,157
Convertible Note
Unamortized discount, current	91,046	0
Unamortized discount, noncurrent	$ 0	$ 188

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Sales	$ 2,011,508	$ 1,804,152
Cost of Sales	1,221,605	980,697
Gross Margin	789,903	823,455
Operating Expenses:
Labor	308,841	312,298
General and Administrative	190,424	147,321
Rent Office Space and Servers	141,495	143,274
Depreciation	116,173	147,547
Legal and Professional	150,477	63,103
Advertising	29,634	18,354
Bad Debt Expense	31,614	68,958
Insurance	28,498	23,070
Travel	15,140	13,097
Management Fees	3,117	3,883
Total Operating Expenses	1,015,413	940,905
Income (Loss) from Operations	(225,510)	(117,450)
Other Income and (Expenses):
Amortization of Debt Discount	(220,662)	(140,160)
Interest & Penalties Expense	(186,172)	(145,256)
Derivative Liability Gains (Losses)	(25,645)	0
Foreign Currency Gains (Losses)	(408)	2,903
Provision for Income Taxes	(86)	0
Other Income	1,297	6,818
Total Other Income (Expenses)	(431,676)	(275,695)
Net Loss	(657,186)	(393,145)
Cumulative Translation Adjustments	52,974	2,886
Total Other Comprehensive Income (Loss)	52,974	2,886
Total Comprehensive Loss	$ (604,212)	$ (390,259)
Basic and Diluted Loss per Share	$ (0.016)	$ (0.015)
Weighted Average Shares Outstanding - Basic and Diluted	37,362,346	26,047,481

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (657,186)	$ (393,145)
Adjustments to Reconcile Net Loss to Net Cash from Operating Activities:
Depreciation	116,173	147,547
Bad Debt Expense	31,614	68,958
Amortization of Debt Discount	220,662	140,160
Stock-based compensation	0	39,100
Foreign currency transaction (Gain) Loss	(5,880)	275
Derivative Liability	208,731	0
Derivative Liability (Gain) Loss	(30,086)	0
Changes in operating assets and liabilities:
Accounts Receivable, Net of Allowance for Doubtful Accounts	5,832	12,727
Prepaid Expenses	33,483	4,981
Accounts Payable and Accrued Liabilities	324,453	142,122
NET CASH AND CASH EQUIVALENTS FROM OPERATING ACTIVITIES	247,796	162,725
CASH FLOWS FROM INVESTING ACTIVITIES:
Deposit on Leasehold Improvements	0	0
Equipment Purchase	(13,895)	(19,464)
NET CASH FROM INVESTING ACTIVITIES	(13,895)	(19,464)
CASH FLOWS FROM FINANCING ACTIVITIES
Bank Overdraft	35,171	0
Proceeds from Promissory Notes	0	0
Proceeds from Convertible Debt	0	0
Royalty Fee Payment	0	0
Principal Payments on Promissory Notes	(180,578)	(90,035)
Principal Payments on Convertible Notes	(78,000)	(15,000)
Principal Payments on Capital Lease Obligations	(36,889)	(30,190)
NET CASH AND CASH EQUIVALENTS FROM FINANCING ACTIVITIES	(260,296)	(135,225)
Gain (Loss) due to foreign currency translation	52,974	2,886
NET CHANGE IN CASH AND CASH EQUIVALENTS	26,579	10,922
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	34,956	85,455
CASH AND CASH EQUIVALENTS AT END OF PERIOD	61,535	96,377
Cash paid during the year for:
Interest	33,368	58,038
Income Taxes	0	0
Non-cash financing and investing activities:
Shares Issued for Convertible Note	80,000	0
Derivative	0	0
Acquisition Liability Assigned to Loan Payable	0	0
Acquisition Liability Assigned to Promissory Note	0	0
Equipment purchased under Capital Lease	0	0
Accrued Interest converted to Note	$ 0	$ 0

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	Note 1. Organization and Summary of Significant Accounting Policies Organization and Basis of Presentation Medical Imaging Corp., (“MIC” or the “Company”), a Nevada Corporation was incorporated in 2000. In 2005, the Company developed a business plan for private healthcare opportunities in Canada with the objective of owning and operating private diagnostic imaging clinics. In 2009, the Company purchased Canadian Teleradiology Services Inc., which operates as: Custom Teleradiology Services (“CTS”). CTS provides remote reading of medical diagnostic imaging scans for rural hospitals and clinics in Canada. In early 2010, the Company modified its business plan to grow its CTS subsidiary while commencing the acquisition of existing imaging clinics located in the United States and exploring the development of new diagnostic imaging technology. In 2012, the Company purchased Schuylkill Open MRI Inc., which operates as: Schuylkill Medical Imaging (“SMI”), an independent diagnostic imaging facility located in Pottsville, Pennsylvania. In 2014, the Company purchased Partners Imaging Center of Venice, LLC (“PIV”) located in Venice, Florida; Partners Imaging Center of Naples, LLC (“PIN”) located in Naples, Florida; and Partners Imaging Center of Charlotte, LLC (“PIC”) located in Port Charlotte, Florida. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31. Principle of Consolidation The consolidated financial statements include the accounts of Medical Imaging, Corp., and its wholly-owned subsidiaries, CTS, SMI, PIV, PIN, and PIC. Intercompany accounts and transactions have been eliminated in the consolidated financial statements. CTS’, SMI’s, PIV’s, PIN’s, and PIC’s accumulated earnings prior to their acquisitions are not included in the consolidated balance sheet. Use of Estimates and Assumptions The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the consolidated financial statements are published, and (iii) the reported amount of net sales, expenses and costs recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of consolidated financial statements; accordingly, actual results could differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At March 31, 2018, and December 31, 2017, cash includes cash on hand and cash in the bank. Accounts Receivable Credit Risk The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio. Management evaluates various factors including expected losses and economic conditions to predict the estimated realization on outstanding receivables. In connection with the acquisition of the three facilities located in Venice, Port Charlotte and Naples, Florida, the Company, in October 2014, entered into professional services agreements whereby the seller of those three facilities continued to handle the billing and collection for the imaging centers (the “third party billing”). The seller must still provide a full set of verification data to the Company with respect to its account receivable processing and collections so that the Company can determine the extent to which accounts submitted by the seller in connection with the third-party billing have been collected or denied. Final verification will only be able to be completed after the conclusion of the services performed pursuant to the third-party billing contract, and review of account balances which is expected during the 2017 fiscal year. As of March 31, 2018 and December 31, 2017, respectively, the allowance for doubtful accounts from direct billings was $280,275 and $266,254. The allowance for doubtful accounts from third party billings (Florida operations) was $348,205 and $330,612. Although the gross receivable balance has increased significantly, management is actively pursuing collection efforts directly with patients and insurance payers and believes that the current allowance for doubtful accounts is sufficient to cover any expected losses. Goodwill and Indefinite - Lived Intangible Assets The Company follows the provisions of Financial Accounting Standard Accounting Standards Codification (“ASC”) 350, Goodwill and Other Intangible Assets Revenue Recognition The Company holds contracts with several hospitals and groups of health care facilities to provide Teleradiology services for a specific period of time. The Company bills for services rendered on a monthly basis. For the year ended December 31, 2017, CTS held seven contracts; four contracts that are renewable on a year-to-year basis and one contract that renewed in 2016 and one to be renewed in 2018. In accordance with the requirement of Staff Accounting Bulletin (“SAB”) 104, the Company recognizes revenue when: (1) persuasive evidence of an arrangement exists (contracts); (2) delivery has occurred (monthly); (3) the seller’s price is fixed or determinable (per the customer’s contract, and services performed); and (4) collectability is reasonably assured (based upon our credit policy). Revenue is accounted for under the guidelines established by SAB 101, Revenue Recognition in Financial Statements, Revenue Recognition Cost of Sales Cost of sales includes fees paid to radiologists for reading services, transcription fees, equipment repairs, system license and usage costs. Impairment of Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment, Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Stock Based Compensation The Company follows ASC 718, Stock Compensation The Company measures all share-based payments to employees (which includes non-employee Board of Directors), including employee stock options, warrants and restricted stock, at the fair value of the award and expenses it over the requisite service period (generally the vesting period). The fair value of common stock options or warrants granted to employees is estimated at the date of grant using the binomial option pricing model (“BOPM”). The calculation also takes into account the common stock fair market value at the grant date, the exercise price, the expected life of the common stock option or warrant, the dividend yield and the risk-free interest rate. The Company from time to time may issue stock options, warrants and restricted stock to acquire goods or services from third parties. Restricted stock, options or warrants issued to other than employees or directors are recorded on the basis of their fair value. The options or warrants are valued using the BOPM on the basis of the market price of the underlying equity instrument on the “valuation date,” which for options and warrants related to contracts that have substantial disincentives to non-performance, is the date of the contract, and for all other contracts is the vesting date. Expenses related to the options and warrants are recognized on a straight-line basis over the period which services are to be received. There was no stock-based compensation expense to non-employees for the three months ended March 31, 2018 and 2017. There was no stock-based compensation expense to employees for the three months ended March 31, 2018. For the three months ended March 31, 2017, the Company recognized stock-based compensation expenses of $8,500 from stock options and $30,600 from stock granted to employees. The options were valued using the BOPM and included in the labor operating expenses in the consolidated statements of operations. Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced sale or liquidation. The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses, accounts payable, accrued liabilities and notes and loans payable approximate fair value due to their most maturities. Fair Value Measurements The Company follows ASC 820, Fair Value Measurements and Disclosures Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the accounts receivable, accounts payable, notes payable are considered short term in nature and therefore their value is considered fair value. Financial assets and liabilities measured at fair value on a recurring basis are summarized below for the three months ended March 31, 2018: Level 1 Level 2 Level 3 Total Liabilities Derivative Financial Instruments $ - $ - $ 116,803 $ 116,803 Foreign Currency Translation The Company’s functional currency for its wholly-owned subsidiary, CTS, is the Canadian dollar, and their financial statements have been translated into U.S. dollars. The Canadian dollar accounts of the Company’s foreign operations have been translated into United States dollars using the current rate method. Assets and liabilities of those operations are translated into U.S. dollars using exchange rates as of the balance sheet date; income and expenses are translated using the weighted average exchange rates for the reporting period. Translation adjustments are recorded as accumulated other comprehensive income (loss), a separate component of stockholders’ equity. The Company recognized a foreign currency gain (loss) on transactions from operations of $(408) for the three months ended March 31, 2018 and $2,903 for the three months ended March 31, 2017. The Company recognized other comprehensive income (loss) of $52,974 for the three months ended March 31, 2018 and $2,886 for the three months ended March 31, 2017. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes Net Income (Loss) Per Share The Company follows the provisions of ASC 260, Earnings per Share Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock or conversion of notes into shares of the Company’s common stock that could increase the number of shares outstanding and lower the earnings per share of the Company’s common stock. This calculation is not done for periods in a loss position as this would be antidilutive. Recent Accounting Updates The Company does not expect the adoption of any recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

Interim Financial Statements

Interim Financial Statements	3 Months Ended
	Mar. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Statements	Note 2. Interim Financial Statements The accompanying interim unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the financial statements and footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 3. Property and Equipment Property and equipment are stated at cost. Depreciation is calculated using the straight - line method over the estimated useful life of the assets. At March 31, 2018 and December 31, 2017, the major class of property and equipment were as follows: March 31, December 31, Estimated useful 2018 2017 lives Computer/Office Equipment $ 184,638 $ 129,535 3-7 years Medical Equipment 2,067,313 2,067,313 3-7 years Leasehold Improvements 884,874 870,980 5-39 years Computer/Office Equipment under capital lease 346,058 404,085 3-5 years Medical Equipment under capital lease 224,412 224,412 5 years Less: Accumulated Depreciation (2,098,945) (1,985,408) Net Book Value $ 1,608,350 $ 1,710,917 Depreciation expense was $116,173 and $147,547 for the three months ended March 31, 2018 and 2017, respectively.

Operating Lease Commitments

Operating Lease Commitments	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
Operating Lease Commitments	Note 4. Operating Lease Commitments SMI entered into a lease commitment for its office space in Pottsville, Pennsylvania. The lease will expire on July 30, 2021. Monthly rental amounts are $6,908 per month not including utilities, realty taxes, and operating costs. SMI has a lease for its x-ray equipment space in Pottsville, Pennsylvania. The lease term is seven years from commitment date of October 2014. Monthly lease payments are $2,000. SMI has a lease for use of x-ray equipment and space in Pottsville, Pennsylvania. The lease term is two years from commitment date of January 2016. Monthly lease payments are $3,000. PIV has a lease for office space in Venice, Florida. The lease will expire September 30, 2021. Monthly rental amounts are $13,170 per month. PIN has a lease for office space in Naples, Florida. The lease will expire January 1, 2020. Monthly rental amounts are $9,543 per month. PIC has a lease for office space in Port Charlotte, Florida. The lease will expire June 20, 2021. Monthly rental amounts are $5,512 per month. Expected lease commitments as of March 31, 2018: Year Total 2018 384,597 2019 512,796 2020 398,280 2021 260,358 Thereafter - $ 1,556,031

Capital Lease Obligations

Capital Lease Obligations	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
Capital Lease Obligations	Note 5. Capital Lease Obligations A detailed summary of the capital lease obligations is as follows: Description Monthly payments Maturity Date APR March 31, 2018 Balance December 31, 2017 Balance SMI X-Ray Machine $ 1,495 15-Aug-19 6.32 $ 24,255 $ 28,315 SMI PACS/RIS System 3,115 1-Nov-19 5.69 59,303 67,725 SMI Copier 135 1-Aug-18 27.63 631 976 SMI Ascentrium 2,450 18-Nov-18 21.48 16,694 22,924 PIV,PIN,PIC PACS/RIS 3,094 1-Jan-20 4.22 65,392 73,925 PIV,PIN,PIC Digital Printers 423 24-Feb-19 9.9 4,428 5,568 CTS Computer - 2-Feb-18 2.25 (0) 1,163 PIN CT Lease 2,332 1-Aug-19 0 39,644 46,640 Total $ 13,044 $ 210,348 $ 247,236 *Annual Percentage Rate (“APR”). Minimum future lease payments under the capital leases as of March 31, 2018 are as follow: Minimum Lease Payments Total 2018 112,774 2019 102,857 2020 3,094 Total minimum lease payments 218,725 Less amount representing interest 8,378 Present value of minimum lease payments 210,347 Less current portion of minimum lease payments 136,580 Long-term capital lease obligations at March 31, 2018 $ 73,767

Promissory Notes

Promissory Notes	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Promissory Notes	Note 6. Promissory Notes A detailed summary of the promissory notes is as follows: Issuance Date Maturity Date APR Payment Amount Payments Frequency March 31, 2018 Face Value Balance December 31, 2017 Face Value Balance 16-Feb-16 23-Feb-17 12.00 % 1,000 Monthly $ 100,000 $ 100,000 22-Feb-16 31-Aug-17 25.00 % 10,417 Monthly 500,000 500,000 22-Mar-16 22-Mar-17 12.00 % - Monthly - 70,000 1-Jul-16 1-Aug-17 20.00 % 20,000 Monthly 104,000 160,000 18-May-17 1-Jul-19 20.00 % 15,000 Monthly* 165,000 165,000 8-Sep-17 30-Mar-18 19.00 % 3,667 Weekly - 44,741 11-Jan-18 27-Jul-18 18.00 % 3,788 Weekly 67,422 - 28-Jul-17 26-Jul-18 39.00 % 1,419 Daily - 237,584 20-Mar-18 28-Jan-19 39.00 % 1,145 Daily 212,288 - 7-Aug-17 16-Oct-18 33.00 % 213 Daily 29,579 42,560 Total Face Value 1,178,289 1,319,885 Unamortized Discount (155,418) (150,360) Total $ 1,022,871 $ 1,169,525 * Scheduled monthly payments of $15,000 for promissory note issued on May 18, 2017 will begin September 1, 2018. **Annual Percentage Rate (“APR”)

Convertible Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Convertible Notes	Note 7. Convertible Notes On July 7, 2017 the Company issued a $153,000 convertible note to a non-affiliate. The note pays interest at a rate of 12% per annum, payable at maturity. The note holder has the right at any time following the initial 180 days of note issuance, to convert all or any part of the outstanding and unpaid principal amount of this note to shares of common stock. The conversion price shall equal the variable conversion price of 65% multiplied by the market price. The market price shall mean the average of the lowest three (3) VWAP’s for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. “VWAP” shall mean the daily dollar volume-weighted average sale price for the common stock on the principal market on any particular trading day. Conversion is subject to limitation of 4.99% beneficial ownership of the outstanding shares of common stock. The notes maturity is January 5, 2019. Prepayment on the note within one hundred twenty-one (121) day from the issue date and ending one hundred eighty (180) days following the issue day is subject to 120% Prepayment amount. On December 5, 2012 and March 27, 2013, the Company sold, through a private placement to accredited investors, three-year 12% convertible notes (“Series B Notes”) in the aggregate principal amount of $1,865,000, and $365,000, respectively. The Notes pay interest at a rate of 12% per annum, payable to the holder at 1% per month, and are convertible into common shares of the Company at $0.10 per share. In addition, each purchaser of the Notes received shares dependent on the dollar amount of Notes purchased. The total number of shares of common stock issued was 5,315,000 shares. On December 1, 2015, the holders of $1,840,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to July 1, 2017 from its original maturity date of December 31, 2015. As part of the extension the Company issued warrants to entitle the holders to purchase up to 1,840,000 shares of common stock at an exercise price of $0.07 per share at any time from December 1, 2015 to July 1, 2018. The Company has valued the warrants at $0.0058 per issued share and recorded a total discount of $10,672 to be amortized over the 18-month extension period. On March 31, 2016, the holders of $50,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to September 1, 2017 from its original maturity date of March 31, 2016. As part of the extension the Company issued warrants to entitle the holders to purchase up to 50,000 shares of common stock at an exercise price of $0.07 per share at any time from March 31, 2016 to September 30, 2018. The Company has valued the warrants at $0.00278 per issued share and recorded a total discount of $139 to be amortized over the 18-month extension period. On March 31, 2016, the holder of $25,000 Series B Notes has agreed to extend the maturity date of the debt outstanding to September 1, 2019 from its original maturity date of March 31, 2016. As part of the extension the Company issued warrants to entitle the holders to purchase up to 25,000 shares of common stock at an exercise price of $0.07 per share at any time from March 31, 2016 to September 30, 2019. The Company has valued the warrants at $0.00583 per issued share and recorded a total discount of $146 to be amortized over the 30-month extension period. On May 22, 2014, the Company sold, through private placement to accredited investors, three-year 12% convertible notes (“Series C Notes”) in the aggregate principal amount of $95,000. The Notes bear interest at a rate of 12% per annum, payable to the holder at1% per month, with the principal amount due on May 31, 2017. The Notes are convertible into shares of the Company’s common stock at an initial conversion rate of $0.15 per share. In addition, each holder of Series C Notes received shares dependent on the dollar amount of Notes purchased. On August 25, 2014, October 31, 2014 and February 17, 2015, the Company sold an additional $75,000, $50,000 and $20,000, respectively of Series C Notes. The total number of shares of common stock issued was 240,000 shares. On March 26, 2014, the Company issued a $300,000 convertible note to a non-affiliate. The note pays interest at a rate of 12% per annum, payable to the holder at 1% per month. In addition to interest payments, the Company is making monthly payments of $5,000 towards the principal balance beginning June 1, 2014 until the note due date of February 28, 2018. The note is convertible into common shares of the Company at $0.15 per share. In addition, the purchaser of the note received 300,000 shares as part of the note agreement. As of March 31, 2018, principal balance of the note was $97,082. In accordance with ASC 470, Debt with conversion and other options, In accordance with ASC 480, Distinguishing Liabilities from Equity, • The debt can be transferred without the transfer of the warrants. • The warrants can be transferred without the transfer of the debt. • The warrants can be exercised while debt still outstanding. In accordance with ASC 470, if the warrants are classified as equity, then the proceeds should be allocated based on the relative fair values of the base instrument and the warrants were valued at $0.0058 per issued share and recorded a total discount of $10,672 to be amortized over 18 months’ extension period. Amortization of the discount for the three months ended March 31, 2018 and 2017 was $0 and $1,773, respectively. A detailed summary of the convertible notes is as follows: Issuance Date Maturity Date APR Conversion Rate Monthly Payment March 31, 2018 Face Value Balance December 31, 2017 Face Value Balance 3-Dec-12 1-Jul-17 12.0 % $ 0.10 $ 250 $ 25,000 $ 25,000 27-Mar 13 1-Jul-17 12.0 0.10 750 45,000 75,000 3-Dec-12 1-Jul-17 12.0 0.10 250 50,000 50,000 3-Dec-12 1-Jul-17 12.0 0.10 260 26,000 26,000 3-Dec-12 1-Jul-17 12.0 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.0 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.0 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.0 0.10 15,000 1,500,000 1,500,000 3-Dec-12 1-Jul-17 12.0 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.0 0.10 150 15,000 15,000 3-Dec-12 1-Jul-18 12.0 0.01 - 237 237 27-Mar-13 30-Sep-17 12.0 0.10 250 25,000 25,000 27-Mar-13 30-Sep-17 12.0 0.10 250 25,000 25,000 27-Mar-13 30-Sep-19 12.0 0.10 250 25,000 25,000 22-May-14 31-May-17 12.0 0.15 500 50,000 50,000 22-May-14 31-May-17 12.0 0.15 225 22,500 22,500 22-May-14 31-May-17 12.0 0.15 225 22,500 22,500 25-Aug-14 31-Jul-17 12.0 0.15 500 50,000 50,000 25-Aug-14 31-Jul-17 12.0 0.15 250 25,000 25,000 31-Oct-14 31-Oct-17 12.0 0.15 500 50,000 50,000 17-Feb-15 17-Feb-18 12.0 0.15 200 20,000 20,000 8-Feb-18 28-Feb-19 12.0 0.1 800 80,000 - 26-Mar-14 28-Feb-18 12.0 0.15 5,971 97,082 125,082 7-Jul-17 5-Jan-19 12.0 Variable - 103,000 153,000 Total Face Value $ 2,381,319 $ 2,409,319 Unamortized Discount (91,194) (188) Total $ 2,290,125 $ 2,409,131 Following are maturities of the long –term debt as of March 31, 2018: Principal Payments 2017 $ 2,056,237 2018 117,082 2019 208,000 Total $ 2,381,319

Royalty Financing

Royalty Financing	3 Months Ended
	Mar. 31, 2018
Royalty Financing Abstract
Royalty Financing	Note 8. Royalty Financing On October 31, 2014, the Company entered into a royalty purchase agreement with Grenville Strategic Royalty Corp. (“Grenville”) for the amount of $2,000,000. The agreement calls for a monthly payment to Grenville based on a percentage of the total of certain revenue items and subject to a monthly minimum payment amount until $8,000,000 has been paid. The amount financed is recorded net of discount to be amortized during the term. For the three months ended March 31, 2018 and 2017, the Company has recorded discount amortization expense of $106,374 and $106,345, respectively. The balance as shown on the consolidated balance sheet as of March 31, 2018 was long term portion of $1,071,393, net of $4,345,841 in unamortized discount and a current portion of $1,467,724. The balance as shown on the consolidated balance sheet as of December 31, 2017 shows a long term portion of $1,108,015, net of $4,452,157 in unamortized discount and a current portion of $1,324,768. As of March 31, 2018, the Company paid a total of $689,723 in royalty payments, additionally the Company has accrued $895,899 in unpaid royalty fees from August 2016 to March 2018.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 9. Related Party Transactions During January 2018, the Company entered into a renewed agreement with a company that is owned and controlled by a major shareholder to provide consulting services. Fees payable for performance of the consulting services are $13,000 per month. The previous agreement with the consultant paid at signing of the agreement, four million two hundred thousand (4,200,000) options to purchase common stock of the client at an exercise price of $0.15 per share with an expiry date of December 31, 2019. The options have a five (5) year term. Inputs used in Binomial Option Pricing model were as follow: stock price at grant date: $0.0517, exercise price $0.15, expected life of the option two and a half (2.5) years, volatility of 70%, and a risk free rate of 0.03%. The options were recorded on the grant date at a value of $34,683. Fees incurred to the related party consultant for the three months ended March 31, 2018 and 2017 were $39,000 and $30,000, respectively, and are included as an expense in Legal and Professional fees in the accompanying statement of operations for the period.

Common Stock Transactions

Common Stock Transactions	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Common Stock Transactions	Note 10. Common Stock Transactions On February 12, 2018, 1,006,711 shares were issued for the conversion of convertible promissory notes at a value of $15,000. On February 7, 2018, 1,700,000 shares were issued for the conversion of convertible promissory notes at a value of $17,000. On January 17, 2018, 865,801 shares were issued for the conversion of convertible promissory notes at a value of $20,000. On January 10, 2018, 627,615 shares were issued for the conversion of convertible promissory notes at a value of $15,000.

Income Tax

Income Tax	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax	Note 11. Income Tax The Company follows ASC 740, Income Taxes The provisions of ASC 740 require companies to recognize in their financial statements the impact of a tax position if that position is more likely than not to be sustained upon audit, based upon the technical merits of the position. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken on a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure. Management does not believe that the Company has any material uncertain tax positions requiring recognition or measurement in accordance with the provisions of ASC 740. Accordingly, the adoption of these provisions of ASC 740 did not have a material effect on the Company’s financial statements. The Company’s policy is to record interest and penalties on uncertain tax positions, if any, as income tax expense.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note. 12. Going Concern As shown in the accompanying consolidated financial statements, the Company incurred net comprehensive loss of $604,212, and $390,259 for the three months ended March 31, 2018 and 2017, as well as a working capital deficit of $7,538,555 at March 31, 2018. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. Management plans to raise additional financing in order to continue its operations and fulfill its debt obligations in 2018, but there can be no assurances that the plan will be successful. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent events On April 30th, 2018, the Company ceased all patient visits at its imaging centers in Florida, Partners Imaging Center of Venice, LLC, Partners Imaging Center of Naples, LLC and Partners Imaging Center of Port Charlotte, LLC. These centers have been closed and the Company is assisting its lien holder in the selling of the equipment. The Company evaluated subsequent events through the date the consolidated financial statements were issued.

Accounting Policies (Policies)

Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Medical Imaging Corp., (“MIC” or the “Company”), a Nevada Corporation was incorporated in 2000. In 2005, the Company developed a business plan for private healthcare opportunities in Canada with the objective of owning and operating private diagnostic imaging clinics. In 2009, the Company purchased Canadian Teleradiology Services Inc., which operates as: Custom Teleradiology Services (“CTS”). CTS provides remote reading of medical diagnostic imaging scans for rural hospitals and clinics in Canada. In early 2010, the Company modified its business plan to grow its CTS subsidiary while commencing the acquisition of existing imaging clinics located in the United States and exploring the development of new diagnostic imaging technology. In 2012, the Company purchased Schuylkill Open MRI Inc., which operates as: Schuylkill Medical Imaging (“SMI”), an independent diagnostic imaging facility located in Pottsville, Pennsylvania. In 2014, the Company purchased Partners Imaging Center of Venice, LLC (“PIV”) located in Venice, Florida; Partners Imaging Center of Naples, LLC (“PIN”) located in Naples, Florida; and Partners Imaging Center of Charlotte, LLC (“PIC”) located in Port Charlotte, Florida. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31.
Principle of Consolidation	Principle of Consolidation The consolidated financial statements include the accounts of Medical Imaging, Corp., and its wholly-owned subsidiaries, CTS, SMI, PIV, PIN, and PIC. Intercompany accounts and transactions have been eliminated in the consolidated financial statements. CTS’, SMI’s, PIV’s, PIN’s, and PIC’s accumulated earnings prior to their acquisitions are not included in the consolidated balance sheet.
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the consolidated financial statements are published, and (iii) the reported amount of net sales, expenses and costs recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of consolidated financial statements; accordingly, actual results could differ from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At March 31, 2018, and December 31, 2017, cash includes cash on hand and cash in the bank.
Accounts Receivable Credit Risk	Accounts Receivable Credit Risk The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio. Management evaluates various factors including expected losses and economic conditions to predict the estimated realization on outstanding receivables. In connection with the acquisition of the three facilities located in Venice, Port Charlotte and Naples, Florida, the Company, in October 2014, entered into professional services agreements whereby the seller of those three facilities continued to handle the billing and collection for the imaging centers (the “third party billing”). The seller must still provide a full set of verification data to the Company with respect to its account receivable processing and collections so that the Company can determine the extent to which accounts submitted by the seller in connection with the third-party billing have been collected or denied. Final verification will only be able to be completed after the conclusion of the services performed pursuant to the third-party billing contract, and review of account balances which is expected during the 2017 fiscal year.
Goodwill and Indefinite Intangible Assets	Goodwill and Indefinite - Lived Intangible Assets The Company follows the provisions of Financial Accounting Standard Accounting Standards Codification (“ASC”) 350, Goodwill and Other Intangible Assets
Revenue Recognition	Revenue Recognition The Company holds contracts with several hospitals and groups of health care facilities to provide Teleradiology services for a specific period of time. The Company bills for services rendered on a monthly basis. For the year ended December 31, 2017, CTS held seven contracts; four contracts that are renewable on a year-to-year basis and one contract that renewed in 2016 and one to be renewed in 2018. In accordance with the requirement of Staff Accounting Bulletin (“SAB”) 104, the Company recognizes revenue when: (1) persuasive evidence of an arrangement exists (contracts); (2) delivery has occurred (monthly); (3) the seller’s price is fixed or determinable (per the customer’s contract, and services performed); and (4) collectability is reasonably assured (based upon our credit policy). Revenue is accounted for under the guidelines established by SAB 101, Revenue Recognition in Financial Statements, Revenue Recognition
Cost of Sales	Cost of Sales Cost of sales includes fees paid to radiologists for reading services, transcription fees, equipment repairs, system license and usage costs.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment, Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Stock Based Compensation	Stock Based Compensation The Company follows ASC 718, Stock Compensation The Company measures all share-based payments to employees (which includes non-employee Board of Directors), including employee stock options, warrants and restricted stock, at the fair value of the award and expenses it over the requisite service period (generally the vesting period). The fair value of common stock options or warrants granted to employees is estimated at the date of grant using the binomial option pricing model (“BOPM”). The calculation also takes into account the common stock fair market value at the grant date, the exercise price, the expected life of the common stock option or warrant, the dividend yield and the risk-free interest rate. The Company from time to time may issue stock options, warrants and restricted stock to acquire goods or services from third parties. Restricted stock, options or warrants issued to other than employees or directors are recorded on the basis of their fair value. The options or warrants are valued using the BOPM on the basis of the market price of the underlying equity instrument on the “valuation date,” which for options and warrants related to contracts that have substantial disincentives to non-performance, is the date of the contract, and for all other contracts is the vesting date. Expenses related to the options and warrants are recognized on a straight-line basis over the period which services are to be received.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced sale or liquidation. The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses, accounts payable, accrued liabilities and notes and loans payable approximate fair value due to their most maturities.
Fair Value Measurements	Fair Value Measurements The Company follows ASC 820, Fair Value Measurements and Disclosures Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the accounts receivable, accounts payable, notes payable are considered short term in nature and therefore their value is considered fair value.
Foreign Currency Translation	Foreign Currency Translation The Company’s functional currency for its wholly-owned subsidiary, CTS, is the Canadian dollar, and their financial statements have been translated into U.S. dollars. The Canadian dollar accounts of the Company’s foreign operations have been translated into United States dollars using the current rate method. Assets and liabilities of those operations are translated into U.S. dollars using exchange rates as of the balance sheet date; income and expenses are translated using the weighted average exchange rates for the reporting period. Translation adjustments are recorded as accumulated other comprehensive income (loss), a separate component of stockholders’ equity.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes
Net Income (Loss) Per Share	Net Income (Loss) Per Share The Company follows the provisions of ASC 260, Earnings per Share Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock or conversion of notes into shares of the Company’s common stock that could increase the number of shares outstanding and lower the earnings per share of the Company’s common stock. This calculation is not done for periods in a loss position as this would be antidilutive.
Recent Accounting Updates	Recent Accounting Updates The Company does not expect the adoption of any recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

Organization and Summary of S20

Organization and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	Level 1 Level 2 Level 3 Total Liabilities Derivative Financial Instruments $ - $ - $ 116,803 $ 116,803

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property Plant and Equipment	March 31, December 31, Estimated useful 2018 2017 lives Computer/Office Equipment $ 184,638 $ 129,535 3-7 years Medical Equipment 2,067,313 2,067,313 3-7 years Leasehold Improvements 884,874 870,980 5-39 years Computer/Office Equipment under capital lease 346,058 404,085 3-5 years Medical Equipment under capital lease 224,412 224,412 5 years Less: Accumulated Depreciation (2,098,945) (1,985,408) Net Book Value $ 1,608,350 $ 1,710,917

Operating Lease Commitments (Ta

Operating Lease Commitments (Tables)	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Year Total 2018 384,597 2019 512,796 2020 398,280 2021 260,358 Thereafter - $ 1,556,031

Capital Lease Obligations (Tabl

Capital Lease Obligations (Tables)	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
Schedule of Capital Leased Obligations	Description Monthly payments Maturity Date APR March 31, 2018 Balance December 31, 2017 Balance SMI X-Ray Machine $ 1,495 15-Aug-19 6.32 $ 24,255 $ 28,315 SMI PACS/RIS System 3,115 1-Nov-19 5.69 59,303 67,725 SMI Copier 135 1-Aug-18 27.63 631 976 SMI Ascentrium 2,450 18-Nov-18 21.48 16,694 22,924 PIV,PIN,PIC PACS/RIS 3,094 1-Jan-20 4.22 65,392 73,925 PIV,PIN,PIC Digital Printers 423 24-Feb-19 9.9 4,428 5,568 CTS Computer - 2-Feb-18 2.25 (0) 1,163 PIN CT Lease 2,332 1-Aug-19 0 39,644 46,640 Total $ 13,044 $ 210,348 $ 247,236
Schedule of Future Minimum Lease Payments for Capital Leases	Minimum Lease Payments Total 2018 112,774 2019 102,857 2020 3,094 Total minimum lease payments 218,725 Less amount representing interest 8,378 Present value of minimum lease payments 210,347 Less current portion of minimum lease payments 136,580 Long-term capital lease obligations at March 31, 2018 $ 73,767

Promissory Notes (Tables)

Promissory Notes (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Schedule of Promissory Notes	Issuance Date Maturity Date APR Payment Amount Payments Frequency March 31, 2018 Face Value Balance December 31, 2017 Face Value Balance 16-Feb-16 23-Feb-17 12.00 % 1,000 Monthly $ 100,000 $ 100,000 22-Feb-16 31-Aug-17 25.00 % 10,417 Monthly 500,000 500,000 22-Mar-16 22-Mar-17 12.00 % - Monthly - 70,000 1-Jul-16 1-Aug-17 20.00 % 20,000 Monthly 104,000 160,000 18-May-17 1-Jul-19 20.00 % 15,000 Monthly* 165,000 165,000 8-Sep-17 30-Mar-18 19.00 % 3,667 Weekly - 44,741 11-Jan-18 27-Jul-18 18.00 % 3,788 Weekly 67,422 - 28-Jul-17 26-Jul-18 39.00 % 1,419 Daily - 237,584 20-Mar-18 28-Jan-19 39.00 % 1,145 Daily 212,288 - 7-Aug-17 16-Oct-18 33.00 % 213 Daily 29,579 42,560 Total Face Value 1,178,289 1,319,885 Unamortized Discount (155,418) (150,360) Total $ 1,022,871 $ 1,169,525

Convertible Notes (Tables)

Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Schedule of Convertible Debt	Issuance Date Maturity Date APR Conversion Rate Monthly Payment March 31, 2018 Face Value Balance December 31, 2017 Face Value Balance 3-Dec-12 1-Jul-17 12.0 % $ 0.10 $ 250 $ 25,000 $ 25,000 27-Mar 13 1-Jul-17 12.0 0.10 750 45,000 75,000 3-Dec-12 1-Jul-17 12.0 0.10 250 50,000 50,000 3-Dec-12 1-Jul-17 12.0 0.10 260 26,000 26,000 3-Dec-12 1-Jul-17 12.0 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.0 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.0 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.0 0.10 15,000 1,500,000 1,500,000 3-Dec-12 1-Jul-17 12.0 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.0 0.10 150 15,000 15,000 3-Dec-12 1-Jul-18 12.0 0.01 - 237 237 27-Mar-13 30-Sep-17 12.0 0.10 250 25,000 25,000 27-Mar-13 30-Sep-17 12.0 0.10 250 25,000 25,000 27-Mar-13 30-Sep-19 12.0 0.10 250 25,000 25,000 22-May-14 31-May-17 12.0 0.15 500 50,000 50,000 22-May-14 31-May-17 12.0 0.15 225 22,500 22,500 22-May-14 31-May-17 12.0 0.15 225 22,500 22,500 25-Aug-14 31-Jul-17 12.0 0.15 500 50,000 50,000 25-Aug-14 31-Jul-17 12.0 0.15 250 25,000 25,000 31-Oct-14 31-Oct-17 12.0 0.15 500 50,000 50,000 17-Feb-15 17-Feb-18 12.0 0.15 200 20,000 20,000 8-Feb-18 28-Feb-19 12.0 0.1 800 80,000 - 26-Mar-14 28-Feb-18 12.0 0.15 5,971 97,082 125,082 7-Jul-17 5-Jan-19 12.0 Variable - 103,000 153,000 Total Face Value $ 2,381,319 $ 2,409,319 Unamortized Discount (91,194) (188) Total $ 2,290,125 $ 2,409,131
Schedule of Maturities of Long-term Debt	Principal Payments 2017 $ 2,056,237 2018 117,082 2019 208,000 Total $ 2,381,319

Organization and Significant Ac

Organization and Significant Accounting Policies - Schedule of Fair Value of Financial Assets and Liabilities (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments	$ 116,803	$ 0
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments	0
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments	0
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments	$ 116,803

Organization and Significant 27

Organization and Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Accounts Receivable, Net, Current
Allowance for doubtful accounts	$ 280,275		$ 266,254
Allowance for doubtful accounts - Third Party Billings (Florida Operations)	348,205		$ 330,612
Recognized Share-Based Compensation Expense
Stock-based compensation expense, stock options	8,500
Stock-based compensation expense, employees	30,600
Foreign Currency Translation
Foreign currency gain (loss)	(408)	$ 2,903
Other comprehensive income (loss)	$ 52,974	$ 2,886

Property and Equipment - Schedu

Property and Equipment - Schedule of Property Plant and Equipment (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, accumulated depreciation	$ (2,098,945)	$ (1,985,408)
Property and equipment, net	1,608,350	1,710,917
Computer/Office Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 184,638	$ 129,535
Property and equipment, estimated useful lives	3-7 years	3-7 years
Medical Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,067,313	$ 2,067,313
Property and equipment, estimated useful lives	3-7 years	3-7 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 884,874	$ 870,980
Property and equipment, estimated useful lives	5-39 years	5-39 years
Computer/Office Equipment under Capital Lease
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 346,058	$ 404,085
Property and equipment, estimated useful lives	3-5 years	3-5 years
Medical Equipment under Capital Lease
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 224,412	$ 224,412
Property and equipment, estimated useful lives	5 years	5 years

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 116,173	$ 147,547

Operating Lease Commitments - S

Operating Lease Commitments - Schedule of Future Minimum Rental Payments for Operating Leases (Details)	Mar. 31, 2018USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity
Year 2,018	$ 384,597
Year 2,019	512,796
Year 2,020	398,280
Year 2,021	260,358
Thereafter	0
Operating Leases, Future Minimum Payments Due	$ 1,556,031

Operating Lease Commitments (De

Operating Lease Commitments (Details Narrative)	3 Months Ended
	Mar. 31, 2018USD ($)
CTS - Office Space - Toronto, Canada
Operating lease, minimum payments	$ 2,600
Leasing arrangements	CTS has a lease commitment for its new office space in Toronto, Canada and the lease will expire April 30, 2021.
SMI - Office Space - Pottsville, Pennsylvania
Operating lease, minimum payments	$ 6,908
Leasing arrangements	SMI entered into a lease commitment for its office space in Pottsville, Pennsylvania and the lease will expire on July 30, 2021.
SMI - X-Ray Equipment
Operating lease, minimum payments	$ 2,000
Leasing arrangements	Lease for x-ray equipment space. The lease term is seven years from commitment date of October 2014.
SMI - X-Ray Equipment #2
Operating lease, minimum payments	$ 3,000
Leasing arrangements	Lease for use of x-ray equipment and space. The lease term is two years from commitment date of January 2016.
Lease Arrangement | PIC
Operating lease, minimum payments	$ 5,512
Leasing arrangements	PIC has a lease for office space in Port Charlotte, Florida. The lease will expire June 20, 2021.
Lease Arrangement | PIN
Operating lease, minimum payments	$ 9,543
Leasing arrangements	PIN has a lease for office space in Naples, Florida. The lease will expire January 1, 2020.
Lease Arrangement | PIV
Operating lease, minimum payments	$ 13,170
Leasing arrangements	PIV has a lease for office space in Venice, Florida. The lease will expire September 30, 2021.

Capital Lease Obligations - Sch

Capital Lease Obligations - Schedule of Capital Lease Obligations (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Capital Leased Assets [Line Items]
Capital lease obligation	$ 210,348	$ 247,233
Capital lease, monthly payments		13,044
SMI - X-Ray Lease
Capital Leased Assets [Line Items]
Capital lease obligation	24,255	28,315
Capital lease, monthly payments	$ 1,495	$ 1,495
Capital lease, maturity date	Aug. 15, 2019	Aug. 15, 2019
Capital lease, annual percentage rate	6.32%	6.32%
SMI - PACS/RIS Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 59,303	$ 67,725
Capital lease, monthly payments	$ 3,115	$ 3,115
Capital lease, maturity date	Nov. 1, 2019	Nov. 1, 2019
Capital lease, annual percentage rate	5.69%	5.69%
SMI Copier Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 631	$ 976
Capital lease, monthly payments	$ 135	$ 135
Capital lease, maturity date	Aug. 1, 2018	Aug. 1, 2018
Capital lease, annual percentage rate	27.63%	27.63%
SMI Ascentrium
Capital Leased Assets [Line Items]
Capital lease obligation	$ 16,694	$ 22,924
Capital lease, monthly payments	$ 2,450	$ 2,450
Capital lease, maturity date	Nov. 18, 2018	Nov. 18, 2018
Capital lease, annual percentage rate	21.48%	21.48%
PV, PN, PC PACS/RIS Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 65,392	$ 73,925
Capital lease, monthly payments	$ 3,094	$ 3,094
Capital lease, maturity date	Jan. 1, 2020	Jan. 1, 2020
Capital lease, annual percentage rate	4.22%	4.22%
PV, PN, PC Digital Printers Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 4,428	$ 5,568
Capital lease, monthly payments	$ 423	$ 423
Capital lease, maturity date	Feb. 24, 2019	Feb. 24, 2019
Capital lease, annual percentage rate	9.90%	9.90%
CTS Computers Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 0	$ 1,163
Capital lease, maturity date	Feb. 2, 2018	Feb. 2, 2018
Capital lease, annual percentage rate		2.25%
PIN CT Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 39,644	$ 46,640
Capital lease, monthly payments	$ 2,332	$ 2,332
Capital lease, maturity date	Aug. 1, 2019	Aug. 1, 2019
Capital lease, annual percentage rate	0.00%	0.00%

Capital Lease Obligations - S33

Capital Lease Obligations - Schedule of Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Capital Leases Future Minimum Payments
Minimum lease payments, 2018	$ 112,774
Minimum lease payments, 2019	102,857
Minimum lease payments, 2020	3,094
Total minimum lease payments	218,725
Less amount representing interest	8,378
Present value of minimum lease payments	210,347
Less current portion of minimum lease payments	136,580	$ 143,501
Long-term Capital Lease Obligations at March 31, 2018	$ 73,767	$ 103,735

Promissory Notes - Schedule of

Promissory Notes - Schedule of Promissory Notes (Details) - USD ($)		3 Months Ended	12 Months Ended
		Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Promissory notes, balance		$ 1,178,289	$ 1,319,885
Unamortized Discount		$ (155,418)	$ (150,360)
Promissory Note #1
Debt Instrument [Line Items]
Promissory note, issuance date		Feb. 16, 2016	Feb. 16, 2016
Promissory note, maturity date		Feb. 23, 2017	Feb. 23, 2017
Promissory note, interest rate		12.00%	12.00%
Promissory notes, payments		$ 1,000	$ 1,000
Promissory notes, payment frequency		Monthly	Monthly
Promissory notes, balance		$ 100,000	$ 100,000
Promissory Note #2
Debt Instrument [Line Items]
Promissory note, issuance date		Feb. 22, 2016	Feb. 22, 2016
Promissory note, maturity date		Aug. 31, 2017	Aug. 31, 2017
Promissory note, interest rate		25.00%	25.00%
Promissory notes, payments		$ 10,417	$ 10,417
Promissory notes, payment frequency		Monthly	Monthly
Promissory notes, balance		$ 500,000	$ 500,000
Promissory Note #3
Debt Instrument [Line Items]
Promissory note, issuance date		Mar. 22, 2016	Mar. 22, 2016
Promissory note, maturity date		Mar. 22, 2017	Mar. 22, 2017
Promissory note, interest rate		12.00%	12.00%
Promissory notes, payments		$ 0	$ 0
Promissory notes, payment frequency		Monthly	Monthly
Promissory notes, balance		$ 0	$ 70,000
Promissory Note #4
Debt Instrument [Line Items]
Promissory note, issuance date		Jul. 1, 2016	Jul. 1, 2016
Promissory note, maturity date		Aug. 1, 2017	Aug. 1, 2017
Promissory note, interest rate		20.00%	20.00%
Promissory notes, payments		$ 20,000	$ 20,000
Promissory notes, payment frequency		Monthly	Monthly
Promissory notes, balance		$ 104,000	$ 160,000
Promissory Note #5
Debt Instrument [Line Items]
Promissory note, issuance date		May 18, 2017	May 18, 2017
Promissory note, maturity date		Jul. 1, 2019	Jul. 1, 2019
Promissory note, interest rate		20.00%	20.00%
Promissory notes, payments		$ 15,000	$ 15,000
Promissory notes, payment frequency	[1]	Monthly	Monthly
Promissory notes, balance		$ 165,000	$ 165,000
Promissory Note #6
Debt Instrument [Line Items]
Promissory note, issuance date		Sep. 8, 2017	Sep. 8, 2017
Promissory note, maturity date		Mar. 30, 2018	Mar. 30, 2018
Promissory note, interest rate		19.00%	19.00%
Promissory notes, payments		$ 3,667	$ 3,667
Promissory notes, payment frequency		Weekly	Weekly
Promissory notes, balance		$ 0	$ 44,741
Promissory Note #7
Debt Instrument [Line Items]
Promissory note, issuance date		Jan. 11, 2018
Promissory note, maturity date		Jul. 27, 2018
Promissory note, interest rate		18.00%
Promissory notes, payments		$ 3,788
Promissory notes, payment frequency		Weekly
Promissory notes, balance		$ 37,422
Promissory Note #8
Debt Instrument [Line Items]
Promissory note, issuance date		Jul. 28, 2017	Jul. 28, 2017
Promissory note, maturity date		Jul. 26, 2018	Jul. 26, 2018
Promissory note, interest rate		39.00%	39.00%
Promissory notes, payments		$ 1,419	$ 1,419
Promissory notes, payment frequency		Daily	Daily
Promissory notes, balance		$ 0	$ 237,584
Promissory Note #9
Debt Instrument [Line Items]
Promissory note, issuance date		Mar. 20, 2018
Promissory note, maturity date		Jan. 28, 2019
Promissory note, interest rate		39.00%
Promissory notes, payments		$ 1,145
Promissory notes, payment frequency		Daily
Promissory notes, balance		$ 212,288
Promissory Note #10
Debt Instrument [Line Items]
Promissory note, issuance date		Aug. 7, 2017	Aug. 7, 2017
Promissory note, maturity date		Oct. 16, 2018	Oct. 16, 2018
Promissory note, interest rate		33.00%	33.00%
Promissory notes, payments		$ 213	$ 213
Promissory notes, payment frequency		Daily	Daily
Promissory notes, balance		$ 29,579	$ 42,560
[1]	Scheduled monthly payments of $15,000 for promissory note issued on May 18, 2017 will begin Septemeber 1, 2018.

Convertible Notes - Schedule of

Convertible Notes - Schedule of Convertible Debt (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Debt Instrument [Line Items]
Convertible note, monthly payment	$ 78,000	$ 15,000
Convertible Note
Debt Instrument [Line Items]
Convertible note, balance	$ 2,381,319		$ 2,409,319
Convertible Note | Note #8
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 15,000		$ 15,000
Convertible note, balance	$ 1,500,000		$ 1,500,000
Convertible Note | Note #7
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #6
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #5
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #4
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 260		$ 260
Convertible note, balance	$ 26,000		$ 26,000
Convertible Note | Note #3
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 50,000		$ 50,000
Convertible Note | Note #2
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013		Mar. 27, 2013
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 750		$ 750
Convertible note, balance	$ 45,000		$ 75,000
Convertible Note | Note #1
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000

Convertible Notes - Schedule 36

Convertible Notes - Schedule of Convertible Debt, Continued #2 (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Debt Instrument [Line Items]
Convertible note, monthly payment	$ 78,000	$ 15,000
Convertible Note
Debt Instrument [Line Items]
Convertible note, balance	$ 2,381,319		$ 2,409,319
Convertible Note | Note #16
Debt Instrument [Line Items]
Convertible note, issuance date	May 22, 2014		May 22, 2014
Convertible note, maturity date	May 31, 2017		May 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 225		$ 225
Convertible note, balance	$ 22,500		$ 22,500
Convertible Note | Note #15
Debt Instrument [Line Items]
Convertible note, issuance date	May 22, 2014		May 22, 2014
Convertible note, maturity date	May 31, 2017		May 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 500		$ 500
Convertible note, balance	$ 50,000		$ 50,000
Convertible Note | Note #14
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013		Mar. 27, 2013
Convertible note, maturity date	Sep. 30, 2017		Sep. 30, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #13
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013		Mar. 27, 2013
Convertible note, maturity date	Sep. 30, 2017		Sep. 30, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #12
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013		Mar. 27, 2013
Convertible note, maturity date	Sep. 30, 2017		Sep. 30, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #11
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2018		Jul. 1, 2018
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.01		$ 0.01
Convertible note, monthly payment	$ 0		$ 0
Convertible note, balance	$ 237		$ 237
Convertible Note | Note #10
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 150		$ 150
Convertible note, balance	$ 15,000		$ 15,000
Convertible Note | Note #9
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 500		$ 500
Convertible note, balance	$ 50,000		$ 50,000

Convertible Notes - Schedule 37

Convertible Notes - Schedule of Convertible Debt, Continued #3 (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Debt Instrument [Line Items]
Convertible note, monthly payment	$ 78,000	$ 15,000
Convertible note, unamortized debt discount	(155,418)		$ (150,360)
Convertible Note
Debt Instrument [Line Items]
Convertible note, balance	2,381,319		2,409,319
Convertible note, unamortized debt discount	(10,672)		(188)
Convertible note, total	$ 2,290,125		$ 2,409,131
Convertible Note | Note #24
Debt Instrument [Line Items]
Convertible note, issuance date	Jul. 7, 2017		Jul. 7, 2017
Convertible note, maturity date	Jan. 5, 2019		Jan. 5, 2019
Convertible note, interest rate	12.00%		12.00%
Convertible note, monthly payment	$ 0		$ 0
Convertible note, balance	$ 103,000		$ 153,000
Convertible Note | Note #23
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 26, 2014		Mar. 26, 2014
Convertible note, maturity date	Feb. 28, 2018		Feb. 28, 2018
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 5,971		$ 5,971
Convertible note, balance	$ 97,082		$ 125,082
Convertible Note | Note #22
Debt Instrument [Line Items]
Convertible note, issuance date	Feb. 8, 2018
Convertible note, maturity date	Feb. 28, 2019		Feb. 28, 2019
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 800
Convertible note, balance	80,000
Convertible note, unamortized debt discount	$ (12,013)
Convertible Note | Note #21
Debt Instrument [Line Items]
Convertible note, issuance date	Feb. 17, 2015		Feb. 17, 2015
Convertible note, maturity date	Feb. 17, 2018		Feb. 17, 2018
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 200		$ 200
Convertible note, balance	$ 20,000		$ 20,000
Convertible Note | Note #20
Debt Instrument [Line Items]
Convertible note, issuance date	Oct. 31, 2014		Oct. 31, 2014
Convertible note, maturity date	Oct. 31, 2017		Oct. 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 500		$ 500
Convertible note, balance	$ 50,000		$ 50,000
Convertible Note | Note #19
Debt Instrument [Line Items]
Convertible note, issuance date	Aug. 25, 2014		Aug. 25, 2014
Convertible note, maturity date	Jul. 31, 2017		Jul. 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #18
Debt Instrument [Line Items]
Convertible note, issuance date	Aug. 25, 2014		Aug. 25, 2014
Convertible note, maturity date	Jul. 31, 2017		Jul. 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 500		$ 500
Convertible note, balance	$ 50,000		$ 50,000
Convertible Note | Note #17
Debt Instrument [Line Items]
Convertible note, issuance date	May 22, 2014		May 22, 2014
Convertible note, maturity date	May 31, 2017		May 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 225		$ 225
Convertible note, balance	$ 22,500		$ 22,500

Convertible Notes - Schedule 38

Convertible Notes - Schedule of Long-Term Debt Maturities (Details)	Mar. 31, 2018USD ($)
Debt Disclosure [Abstract]
Principal payments, 2017	$ 2,056,237
Principal payments, 2018	117,082
Principal payments, 2019	208,000
Total principal payments	$ 2,381,319

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Amortization of debt discount	$ 220,662	$ 140,160
Unamortized debt discount	155,418		$ 150,360
Convertible Note
Additional paid in capital and discount	183,000
Amortization of debt discount	105,006	3,435
Amortization of debt discount, warrants	$ 0	$ 1,773
Warrants issued, value per share	$ 0.0058
Unamortized debt discount	$ 10,672		188
Convertible note, balance	2,381,319		2,409,319
Convertible Note | Individually Issued
Convertible notes issued							$ 300,000
Convertible notes, payment terms							The note pays interest at a rate of 12% per annum, payable to the holder at 1% per month. The Company is making monthly payments of $5,000 towards the principal balance beginning June 1, 2014 until the note due date of February 27, 2018.
Convertible notes, price per share for conversion of shares of common stock							$ 0.15
Convertible notes, interest rate							12.00%
Maturity date							Feb. 28, 2018
Common stock issued							300,000
Convertible notes payable	$ 97,082
Convertible Note | Series C Notes
Convertible notes issued							$ 95,000
Convertible notes, payment terms							Series C Notes bear interest at a rate of 12% per annum, payable to the holder at 1% per month, with principal amount due May 31, 2017.
Convertible notes, price per share for conversion of shares of common stock							$ 0.15
Convertible notes, interest rate							12.00%
Private placement, convertible notes, principal amount						$ 20,000	$ 220,000	[1]
Maturity date							May 31, 2017
Common stock issued						240,000
Convertible Note | Series B Notes
Convertible notes, payment terms									Series B Notes pay interest at a rate of 12% per annum, payable to the holder at 1% per month.
Convertible notes, price per share for conversion of shares of common stock									$ 0.10
Convertible notes, interest rate									12.00%
Private placement, convertible notes, principal amount									$ 2,230,000
Maturity date, description				The holders of $50,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to September 1, 2017. The holder of $25,000 Series B Notes has agreed to extend the maturity date of the debt outstanding to September 1, 2019.		The holders of $1,840,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to July 1, 2017 from its original maturity date of December 31, 2015.
Maturity date				Sep. 30, 2019		Jul. 1, 2017
Common stock issued									5,315,000
Warrants issued, shares				75,000	[2],[3]	1,840,000
Warrants issued, value per share				$ 0.07		$ 0.07
Exercise price						$ 0.0058
Unamortized debt discount				$ 285		$ 10,672
Convertible Note | Non-Affiliate
Convertible notes issued			$ 153,000
Convertible notes, terms of conversion feature			The note holder has the right at any time following the initial 180 days of note issuance, to convert all or any part of the outstanding and unpaid principal amount of this note to shares of common stock. The conversion price shall equal the variable conversion price of 65% multiplied by the market price. The market price shall mean the average of the lowest three (3) VWAP's for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. "VWAP" shall mean the daily dollar volume-weighted average sale price for the common stock on the principal market on any particular trading day. Conversion is subject to limitation of 4.99% beneficial ownership of the outstanding shares of common stock.
Convertible notes, interest rate			12.00%
Maturity date			Jan. 5, 2019
Convertible Note | Note #22
Convertible notes, price per share for conversion of shares of common stock	$ 0.10		$ 0.10
Convertible notes, interest rate	12.00%		12.00%
Unamortized debt discount	$ 12,013
Convertible notes payable	$ 66,987
Convertible note, maturity date	Feb. 28, 2019		Feb. 28, 2019
Convertible note, balance	$ 80,000
Common stock issued, inducement	200,000
[1]	$95,000, $75,000 and $50,000 of Series C Notes were sold on May 22, 2014, August 25, 2014 and October 31, 2014.
[2]	The 25,000 warrants issued are valued at $0.00583 per issued share.
[3]	The 50,000 warrants issued are valued at $0.00278 per issued share.

Royalty Financing (Details Narr

Royalty Financing (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2014	Dec. 31, 2017
Royalty Financing Abstract
Royalty purchase agreement, amount			$ 2,000,000
Royalty purchase agreement			On October 31, 2014, the Company entered into a royalty purchase agreement with Grenville Strategic Royalty Corp. for the amount of $2,000,000. The agreement calls for a monthly payment to the seller based on a percentage of the total of certain revenue items and subject to a minimum payment amount until $8,000,000 has been paid.
Royalty payments	$ 689,723
Discounted amortization expense	106,374	$ 106,345
Royalty Financing, less current portion, net of unamortized discounts	1,071,393			$ 1,108,015
Royalty financing, unamortized discount, noncurrent	4,345,841			4,452,157
Current Portion of Royalty Financing	1,467,724			$ 1,324,768
Accrued royalties	$ 895,899

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Major Shareholder - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Consulting services, description	January 2018, the Company entered into a renewed agreement with a company that is owned and controlled by a major shareholder to provide consulting services. Fees payable for performance of the consulting services are $13,000 per month.
Options granted	4,200,000
Exercise price	$ 0.15
Term of options granted	5 years
Stock price	$ 0.0517
Expected life	2 years 6 months
Volatility	70.00%
Risk free rate	0.03%
Grant date value	$ 34,683
Balance for services rendered	$ 39,000	$ 120,000

Common Stock Transactions (Deta

Common Stock Transactions (Details Narrative) - Common Stock	3 Months Ended
	Mar. 31, 2018USD ($)shares
Shares Issued for Convertible Notes, value | $	$ 80,000	[1]
Shares Issued for Convertible Notes, shares | shares	5,500,127	[2]
[1]	$13,000 for value of shares issued February 22, 2018; $15,000 for value of shares issued February 12, 2018; $17,000 for value of shares issued February 7, 2018; $20,000 for value of shares issued January 17, 2018; $15,000 for value of shares issued January 10, 2018.
[2]	1,300,000 shares issued February 22, 2018; 1,006,711 shares issued February 12, 2018; 1,700,000 shares issued February 7, 2018; 865,801 shares issued January 17, 2018; 627,615 shares issued January 10, 2018.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Total Comprehensive Income (Loss)	$ (604,212)	$ (390,259)
Working capital deficit	$ 7,538,555